AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05036135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via dry powder inhalation
Study NCT06176547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: Blood glucose in last 3 months
Study NCT06342752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Early detection of volatile organic compounds (VOCs) in breath from preterm infants, collected at several timepoints within the first 4 weeks of life to predict BPD before diagnosis is made at 36 weeks PMA.
Study NCT05006066 — intervention group
Intervention type: OTHER
Intervention: Temporal Summation
Description: 4 type of stimulations applied on the right arm
Study NCT05150626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablets, oral
Study NCT06342752 — intervention group
Intervention type: OTHER
Intervention: Throat swabs
Description: A throat swab will be taken on several timepoints within the first 4 weeks of life to detect airway mucin expression. A second throat swab will be taken as proxy for the airway microbiome.
Study NCT06342752 — intervention group
Intervention type: OTHER
Intervention: Placental samples
Description: After birth, placental biopsies will be collected for headspace VOCs analysis. A placental swab and a biopsy will be taken for microbiome analysis.
Study NCT06342752 — intervention group
Intervention type: OTHER
Intervention: Vaginal swab
Description: A vaginal swab will be taken before birth for microbiome analysis.
Study NCT06342752 — intervention group
Intervention type: OTHER
Intervention: Endotracheal aspirates
Description: Collection of aspirates, as part of routine care, to detect mucin expression and the lung microbiome.
Study NCT05201261 — intervention group
Intervention type: DEVICE
Intervention: ltrasonic measure
Description: In the right decubitus position, the spine was scanned with an ultrasonic convex array probe. Starting from the sacrum, the length of each vertebral body of the lumbar spine was measured on a para-midsagittal oblique view. The intervertebral space was located and the width of the subarachnoid space was measured on a midsagittal and transverse view.
Study NCT05472402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LADIES online intervention (R33 phase)
Description: Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.
Study NCT05472402 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LADIES online control (R33 phase)
Description: Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
Study NCT04894071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA102
Description: Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration.
Study NCT04894071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration.
Study NCT04387734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrevus will be administered following the FDA's regulations.
Study NCT04387734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platform
Description: The applications of the platform DMTs will follow the FDA-approved regulations.
Study NCT06068439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: aspirin 50 mg/d to be taken after dinner (in nonfasting conditions)
Study NCT06068439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 50 mg/d to be taken after dinner (in nonfasting conditions)
Study NCT06512623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoadsoprtion
Description: The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge will be measured.
Study NCT05489536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A web/smartphone-based lifestyle program package
Description: There are two platforms for the lifestyle program, namely Health and Nutrition Education (HNE) website and HNE app. The participants are requested to download and register on the HNE website and the HNE app. The HNE app is Android and IOS compatible. Both the HNE website and app are designed to support self-directed learning and independently monitor their GWG and dietary intake during pregnancy. Both the HNE website and app will be passcode protected throughout the study period such that access is restricted to only participants in the intervention group.~The web/smartphone-based lifestyle program package consists of:~I. Health and Nutrition Education (HNE) resources II. Gestational Weight Gain (GWG) monitoring III. Dietary intake monitoring
Study NCT05723133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Description: Patients will receive oral hygiene instructions and an electric toothbrush with or without daily personal feedback using the brushing app (Oral-B app).
Study NCT05723133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
Study NCT05723133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: The same oral hygiene instructions are given to all patients. It is important for the patient to scrupulously follow these oral hygiene instructions at home and carry them out daily.
Study NCT05672927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine, 2 doses alternate timing
Description: Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
Study NCT04829539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Receive BBT-CI
Study NCT04829539 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Receive HEAL
Study NCT04829539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04829539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04829539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05672927 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-valent HPV vaccine, 3 doses standard timing
Description: This will be the comparison group for the 2-dose group.
Study NCT04731584 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
Study NCT04829539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05910918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Care Nurses' Training Package
Description: For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
Study NCT05910918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Care Nurses' Training Package
Description: For the study group, the researcher will explain the method of the training package program application to critical care nurses as follows; firstly, the researchers will assess the nurses' roster, then the researchers will classify the subjects into groups in order to conduct the training package for a group of them while the other subjects taking care of the patients in the intensive care units and repeat the same session to the others in the same manner.
Study NCT05299164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 1
Description: Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study NCT05299164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 2
Description: Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study NCT05299164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 3
Description: Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study NCT05299164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Mitoxantrone Hydrochloride dose level 4
Description: Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study NCT06058416 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Healive (hepatitis A vacine(human diploid cell), inactivated)
Description: The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively.
Study NCT04830501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00434
Description: Once daily \[QD\], 28 days/cycle.
Study NCT06131385 — intervention group
Intervention type: DRUG
Intervention: intravenous thrombolysis
Description: Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
Study NCT05611359 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation
Description: Thermal hepatic ablation Combined with Chemotherapy
Study NCT05611359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy
Study NCT05611359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy
Study NCT05143762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
Study NCT05143762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: patients will receive dexamethasone 0.5mg/kg IV.
Study NCT05143762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: patients will receive placebo 10 ml normal saline IV.
Study NCT06406686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Description: Durable block across the cavotricuspid isthmus by radiofrequency ablation.
Study NCT06406686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter
Description: Durable block across the cavotricuspid isthmus by radiofrequency ablation.
Study NCT06597019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran (inclisiran sodium 300 mg subcutaneous (s.c.) for participants with body weight ≥23 kg and inclisiran sodium 180 mg s.c. for participants with body weight \<23 kg. The dose level is based on the participant's body weight on Day 1 (for Part 1) and Day 360 (for Part 2), respectively.
Study NCT06597019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study NCT06249919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NS101
Description: NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
Study NCT06249919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NS101
Description: NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
Study NCT06096714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine will be infused using a pump.
Study NCT06096714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine
Description: Nicotine will be infused using a pump.
Study NCT06096714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline with be used to compare Nicotine, Saline will be infused using a pump
Study NCT06096714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline with be used to compare Nicotine, Saline will be infused using a pump
Study NCT04904016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx™
Description: The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
Study NCT04970810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes Goal
Description: Subjects enrolled in the MDG arm will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls.
Study NCT04970810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes Goal + CommunityRx
Description: Subjects enrolled in the MDG arm + CRx will receive surveys at baseline, 6 months and 12 months, followed by monthly diabetes care management phone calls. Participants will also receive a HealtheRx (personalized resource prescriptions) for community organizations.
Study NCT06504368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PDL1
Description: Solution for IV Infusion
Study NCT06181318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiparametric MRI scan of the liver
Description: MRI scans will be performed at the Champalimaud Foundation using a 1.5T scanner after patients have fasted for 4 hours. Transverse abdominal T1 maps will be acquired to estimate extracellular fluid (which increases in cases of fibrosis and inflammation) and T2\* maps will be acquired to estimate liver iron levels. These quantitative MRI maps will be laid onto the volumetric images of Couinaud segments. Multi-slice quantitative maps will be generated using Liver MultiScan software (Perspectum, UK) with operators blinded to patient status. T1 measurements will be adjusted for the iron level to give iron-corrected T1 maps (cT1). Reference ranges for cT1 have been defined in the general population. PDFF maps of the liver will be calculated using MRI multi-echo and spoiled-gradient-echo acquisition. No intravenous contrast agents will be used in Liver MultiScan maps and the total scan duration will be approximately 30 minutes.
Study NCT05416450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravaginal electrical stimulation added to bladder training
Description: BT was given as a home program. After information session, squeezing the PFM was shown in practice at least once to use in the urgency suppression strategies via digital palpation technique. The second stage strategies was aimed to delay urination, inhibit detrusor contraction, and prevent urgency by squeezing the PFM several times on a row, breathing deeply and self-motivating. In the third stage, a timed voiding program was started; a timed voiding and increasing the time between urination considering the voiding diary. IVES was applied in addition to BT in both groups. It was performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with a vaginal probe; three days a week, a total of 24 sessions for 8 weeks. Every session lasted 20 minutes. The stimulation parameters were a 10 Hz of frequency, a 5-10 s of work-rest cycle duration and, a 100 ms of pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100 mA.
Study NCT06247085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegtibatinase
Description: Full Target Dose of pegtibatinase BIW
Study NCT06247085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: volume-matched saline SC BIW
Study NCT06108869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABT Online Programme
Description: When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~* A short ABT practice~* An educational component related to the development of our ABT practice~* A group discussion on the week's topic and how it relates to you and your diagnosis
Study NCT06108869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Control group
Description: Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
Study NCT06188754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Limiting food intake to 10 hours per day
Study NCT06188754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
Study NCT05222087 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 35Gy/5# Central 40Gy/5# Large Tumours >5cm (non-central) 36Gy/12# or 40Gy/15# Ultracentral lesions 50Gy/5# Peripheral Tumours ≤5cm
Study NCT05222087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC systemic therapy
Description: Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
Study NCT05222087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC systemic therapy
Description: Permitted SoC chemoimmunotherapy for squamous patients will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel. Carbo/Paclitaxel/Pembro intravenous infusions are given every 3 weeks for cycle 1-4, followed by ongoing maintainence with Pembrolizumab from Cycle 5. For non-squamous patients, SoC chemoimmunotherapy will include single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Permetrexed. Carboplatin/Pemetrexed/Pembrolizumab infusions are given every 3 weeks for four cycles followed by maintenance with Pemetrexed/Pembrolizumab from Cycle 5.
Study NCT05038228 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Anticoagulant
Study NCT05038228 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Anticoagulant
Study NCT05038228 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Anticoagulant
Study NCT05038228 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonist (VKA)
Description: Anticoagulant
Study NCT04833855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab Dose 1
Description: Subcutaneous injection.
Study NCT04833855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab Dose 2
Description: Subcutaneous injection.
Study NCT04833855 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection.
Study NCT04833855 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection.